Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.23.2
Commitments and Contingencies (Details)
£ in Millions
 1 Months Ended 12 Months Ended
Dec. 20, 2022
item
Aug. 18, 2021
lawsuit
Jun. 25, 2021
lawsuit
Jun. 04, 2021
lawsuit
Dec. 31, 2019
USD ($)
D
May 31, 2023
USD ($)
item
May 31, 2023
GBP (£)
Jan. 31, 2022
USD ($)
Jan. 06, 2022
USD ($)
Shareholder Derivative Lawsuits                  
Commitments and Contingencies                  
Number of additional shareholder derivative lawsuits | lawsuit   2 2            
Consolidated number of lawsuits | lawsuit       3          
Securities and Exchange Commission and Department of Justice Investigations | Mr. Pourhassan                  
Commitments and Contingencies                  
Number of conspiracy charges | item 1                
Number of security fraud charges | item 4                
Number of wire fraud charges | item 3                
Number of insider trading charges | item 3                
Securities and Exchange Commission and Department of Justice Investigations | Kazem Kazempour                  
Commitments and Contingencies                  
Number of conspiracy charges | item 1                
Number of security fraud charges | item 3                
Number of wire fraud charges | item 2                
Number of insider trading charges | item 1                
Samsung BioLogics Co., Ltd. ("Samsung")                  
Commitments and Contingencies                  
Forecast period           3 years      
Amount of material breach of' Master Services and Project Specific Agreements | $                 $ 13,500,000
Additional Contractual Obligation | $               $ 22,800,000  
Past due balance | $           $ 232,788,000      
License Agreements With Vyera Pharmaceuticals, LLC                  
Commitments and Contingencies                  
Amount payable upon achievement of sales and regulatory milestone | $         $ 85,300,000        
Percentage of royalty payable by the counter party         50.00%        
Term of arrangement         10 years        
Term of arrangement, after first commercial sale         2 years        
Number of days of prior written notice | D         180        
Progenics Purchase Agreement                  
Commitments and Contingencies                  
Amount of milestone payments payable | $           $ 5,000,000      
Percentage of royalty payable           3.50%      
Amount payable upon filing BLA with FDA | $           $ 500,000      
Amount payable upon FDA approval | $           500,000      
Annual maintenance fees | $           $ 150,000      
Progenics Purchase Agreement | Royalty Payable in Initial 10 Years                  
Commitments and Contingencies                  
Percentage of royalty payable           5.00%      
Lonza Agreement                  
Commitments and Contingencies                  
Number of contract manufacturers | item           2      
Annual license fee           $ 700,000 £ 0.6    
Royalty on net sales (as a percent)           2.00% 2.00%    
Accounts Payable | Samsung BioLogics Co., Ltd. ("Samsung")                  
Commitments and Contingencies                  
Past due balance | $           $ 33,700,000